Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
The Swiss company SIGVARIS, 100% family-owned since it was founded, is the global market leader in the manufacture of medical compression garments and celebrated its 150th anniversary in 2014. The company was established in 1864 in Winterthur. For about 100 years, SIGVARIS produced “rubber-elastic textiles”, which it sold both in Switzerland and abroad.
From 1958 to 1960, the company collaborated with Dr. Karl Sigg and developed a medical compression stocking to improve venous function and relieve venous-related conditions. The product portfolio was expanded in 2009 when the WELL BEING and SPORTS lines were added to the main MEDICAL line. WELL BEING stockings have a preventive function and relieve the early symptoms of leg conditions. SPORTS products improve athlete performance and recovery time.
The company can look back at a successful track record as it moves continuously towards the future, in keeping with its motto “Every day a step further”. Customers around the world include pharmacies, chemists, orthopaedic and medical specialist stores as well as doctors and hospitals. The Group produced about 8 million pairs of stockings in 2014 and generated revenue of around CHF 250 million.
SIGVARIS Group
The Swiss Group SIGVARIS has its headquarters in Switzerland and is the global market leader in the manufacture of medical compression garments. It employs about 1,400 people and has its own production plants in Switzerland, France, the US and Brazil. SIGVARIS is close to its customers, having subsidiaries in Germany, Austria, England, Italy, Canada, China, Australia and the United Arab Emirates as well as distributors in more than 70 countries on all continents. The Group pursues an international growth strategy on the solid foundation of 150 years of success.
Contact
Rue Barthélémy Thimonnier, 42170 Saint-Just-Saint-Rambert, France
+33 4 77 36 08 90
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
